Advancing our innovative pipeline
to address unmet needs

TransCon Anti-VEGF

Our collaboration partner, Roche Genentech, is applying the TransCon technology to develop anti-vascular endothelial growth factor (anti-VEGF) for the treatment of age-related macular edema (AMD) and other ophthalmic indications.

TransCon anti-VEGF is designed to support up to half-yearly ocular administration frequencies and to provide comparable efficacy to current intravitreal anti-VEGF injections.

Roche Genentech is currently evaluating the safety and efficacy of various TransCon prodrug candidates for intravitreal administration.

Ophthalmic Diseases:
Unmet Needs

Ophthalmic diseases, including neovascular wet AMD, macular edema following retinal vein occlusion and diabetic macular edema, are serious sight-threatening diseases. Without treatment, most patients experience progressive and inevitable vision loss. Anti-VEGF therapies have been transformative in the treatment of these diseases, resulting in patients routinely gaining back significant vision for several years. Lucentis® (ranibizumab) is a leading anti-VEGF drug, and is administered as periodic intravitreal injections. Due to the invasiveness of frequent intravitreal injections, there is a significant unmet medical need for longer acting anti-VEGF therapy.